Aratana Therapeutics

Aratana is uniquely positioned to deliver new, high-quality medicines to address unmet needs in companion animal care. We are committed to bringing world class science to animal health for companion animals and the people who care for them. Our competitive advantage resides in our ability to identify, acquire and develop high-value commercial products for companion animals in a cost effective and efficient manner.

Aratana (PETX) delivered earnings and revenue surprises of -40.00% and 5.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Aratana (PETX) Reports Q1 Loss, Tops Revenue Estimates

Aratana (PETX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aratana (PETX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Elanco Animal Health Inc

Elanco Animal Health Inc. announced Friday that it has struck a deal to buy pet therapeutics company Aratana Therapeutics Inc.

Elanco Animal Health Announces $245M Stock-For-Stock Acquisition Of Aratana Therapeutics

Shares of Aratana Therapeutics shot up 39% in premarket trade on Friday after Elanco Animal Health announced it would be acquiring the pet therapeutics company in a deal worth up to $245 million.

News for Aratana Therapeutics Stock (PETX)